U.S. markets open in 5 hours 35 minutes
  • S&P Futures

    3,920.00
    -2.50 (-0.06%)
     
  • Dow Futures

    31,961.00
    +45.00 (+0.14%)
     
  • Nasdaq Futures

    13,240.00
    -62.00 (-0.47%)
     
  • Russell 2000 Futures

    2,296.90
    +11.80 (+0.52%)
     
  • Crude Oil

    63.60
    +0.38 (+0.60%)
     
  • Gold

    1,787.90
    -10.00 (-0.56%)
     
  • Silver

    27.90
    +0.04 (+0.13%)
     
  • EUR/USD

    1.2209
    +0.0040 (+0.33%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    21.85
    -1.26 (-5.45%)
     
  • GBP/USD

    1.4151
    +0.0009 (+0.07%)
     
  • USD/JPY

    106.1100
    +0.2280 (+0.22%)
     
  • BTC-USD

    50,079.45
    -178.62 (-0.36%)
     
  • CMC Crypto 200

    999.84
    +5.18 (+0.52%)
     
  • FTSE 100

    6,680.91
    +21.94 (+0.33%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Recap: Bristol-Myers Squibb Q3 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Bristol-Myers Squibb (NYSE:BMY) moved higher by 1.4% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 39.32% year over year to $1.63, which beat the estimate of $1.49.

Revenue of $10,540,000,000 up by 75.46% year over year, which beat the estimate of $10,330,000,000.

Outlook

Bristol-Myers Squibb hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 05, 2020

View more earnings on BMY

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/wcc/r/2191341/2E422DEDBD61B35941959E79E4F65940

Recent Stock Performance

Company's 52-week high was at $68.34

Company's 52-week low was at $45.76

Price action over last quarter: Up 8.75%

Company Overview

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.